Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Nuevolution, Boehringer Ingelheim form new collaboration
November 2011
SHARING OPTIONS:

COPENHAGEN—Nuevolution A/S recently entered into a collaboration with Boehringer Ingelheim, with Nuevolution's proprietary Chemetics drug discovery technology at the core of the agreement. Under the collaboration, hundreds of millions of diverse small molecules will be screened in order to determine and advance potential drug candidates against targets of interest to Boehringer Ingelheim. Per the agreement, Boehringer Ingelheim will make an upfront payment to Nuevolution, in addition to providing research funding. Nuevolution will be eligible for milestone payments as the molecules move through preclinical and clinical development and to the market, as well as royalties on the sales of approved products. Specific financial details were not disclosed.  
 
Alex Gouliaev, CEO of Nuevolution, noted that the company is "very pleased about the expansion of our partnership portfolio by entering into this drug discovery collaboration with Boehringer Ingelheim."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.